Figure 6. MLA blocked the decrease in sleep onset time and the increase in sleep duration induced by cholinergic activation.
(A) Time to sleep onset for ChAT-ChR2-Sti-MLA, ChAT-ChR2-Sti-Saline, and WT-Sti mice. (B) Total sleep time of ChAT-ChR2-Sti, ChAT-ChR2-NonSti, and WT-Sti mice during 1 hr stimulation period. (C) Duration of waking, NREM, and REM for ChAT-ChR2-Sti-MLA, ChAT-ChR2-Sti-Saline and WT-Sti mice in 1 hr recording. Data represent mean ± SEM (n = 8 mice, *p < 0.05, **p < 0.01, two-tailed t-test between ChAT-ChR2-Sti-MLA mice and either ChAT-ChR2-Sti-Saline or WT-Sti mice). See also Figure 6—figure supplement 1.
Figure 6—figure supplement 1. MLA decreased spontaneous sleep in the daytime.
(A) EEG and EMG trace during 1 hr in the daytime of Chat-ChR2-Saline and Chat-ChR2-MLA mice. (B) Time spent in the wake, NREM and REM stages for Chat-ChR2-Saline and Chat-ChR2-MLA mice. In vivo injection of MLA could decrease spontaneous activity. All data represent mean ± SEM (n = 6 mice, *p < 0.05, **p < 0.01, two-tailed t-test between ChAT-ChR2-MLA and ChAT-ChR2-Saline mice).